Comparative Effectiveness of Clopidogrel vs . Potent P2Y 12 Inhibitors in CYP2C19 Normal Metabolizers Following Percutaneous Coronary Intervention: A Real‐World Cohort Study

Documenti analoghi

• Response to: Comment on ‘comparative effectiveness of clopidogrel vs . potent P2Y12 inhibitors in CYP2C19 normal metabolizers following percutaneous coronary intervention: A real‐world cohort study’
  di: Hsing‐Yu Hsu, et al.
  Pubblicazione: (2026)
• Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention
  di: Danwei Shao, et al.
  Pubblicazione: (2026)
• Ticagrelor versus Adjusted‐Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention
  di: Ming‐Lung Tsai, et al.
  Pubblicazione: (2024)
• Genome‐wide association study and polygenic risk scores of eosinophilia in Taiwan
  di: Hsing‐Fang Lu, et al.
  Pubblicazione: (2025)
• Clinical Outcomes and Safety Profiles of Generic Versus Brand‐Name Clopidogrel in Patients Following Coronary Artery Stent Placement
  di: Chin‐Yuan Chia, et al.
  Pubblicazione: (2025)